Search Results - "Kleih, Markus"

ATF3 characterizes aggressive drug-tolerant persister cells in HGSOC by Böpple, Kathrin, Oren, Yaara, Henry, Whitney S., Dong, Meng, Weller, Sandra, Thiel, Julia, Kleih, Markus, Gaißler, Andrea, Zipperer, Damaris, Kopp, Hans-Georg, Aylon, Yael, Oren, Moshe, Essmann, Frank, Liang, Chunguang, Aulitzky, Walter E.

“…High-grade serous ovarian cancer (HGSOC) represents the most common and lethal subtype of ovarian cancer. Despite initial response to platinum-based standard…”
Get full text

Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA by Heine, Simon, Kleih, Markus, Giménez, Neus, Böpple, Kathrin, Ott, German, Colomer, Dolors, Aulitzky, Walter E, van der Kuip, Heiko, Silkenstedt, Elisabeth

“…Mantle cell lymphoma (MCL) is an aggressive B-non-Hodgkin lymphoma with generally poor outcome. MCL is characterized by an aberrantly high cyclin D1-driven…”
Get full text

Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma by Höring, Elisabeth, Montraveta, Arnau, Heine, Simon, Kleih, Markus, Schaaf, Lea, Vöhringer, Matthias C., Esteve‐Arenys, Anna, Roué, Gael, Colomer, Dolors, Campo, Elias, Ott, German, Aulitzky, Walter E., Kuip, Heiko

“…Summary Imbalances in the composition of BCL2 family proteins contribute to tumourigenesis and therapy resistance of mantle cell lymphoma (MCL), making these…”
Get full text

Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells by Kleih, Markus, Böpple, Kathrin, Dong, Meng, Gaißler, Andrea, Heine, Simon, Olayioye, Monilola A., Aulitzky, Walter E., Essmann, Frank

“…Patients with high-grade serous ovarian cancer (HGSC) frequently receive platinum-based chemotherapeutics, such as cisplatin. Cisplatin binds to DNA and…”
Get full text

Abstract 701: Mitochondrial mass is a critical determinant of cis Pt-induced cell death in ovarian cancer by Kleih, Markus, Böpple, Kathrin, Gaißler, Andrea, Dong, Meng, Aulitzky, Walter E., Essmann, Frank

“…Abstract Platinum compounds are an inherent part of chemotherapy for patients with high grade serous ovarian cancer (HGSC). Platinum based therapeutics, such…”
Get full text

Abstract 653: Ovarian cancer persister cells: 2D and 3D in-depth characterization and analysis by Boepple, Kathrin, Dong, Meng, Gaissler, Andrea, Winkler, Bernd, Kleih, Markus, Essmann, Frank, Aulitzky, Walter E.

“…Abstract Ovarian cancer is one of the five cancer types with highest incidence of death in women. Due to a lack of diagnostic options, timely detection of…”
Get full text

Abstract 3522: Both mitochondrial function and composition of BCL2 family proteins determines sensitivity to Cisplatin in ovarian cancer cells and are promising targets to overcome Cisplatin resistance in ovarian cancer by Kleih, Markus, Heine, Simon, Böpple, Kathrin, Dong, Meng, Kuip, Heiko van der, Aulitzky, Walter E.

“…Abstract Mitochondria are critical target structures of platinum drugs. To study whether mitochondrial activities of Cisplatin are critical for its cytotoxic…”
Get full text

Abstract 5085: A preclinical model using perfusion air culture of tumor tissue slices for personalized medicine by Dong, Meng, Böpple, Kathrin, Winkler, Bernd, Kleih, Markus, Schüler, Julia, Davies, Emma, Metsalu, Tauno, Walles, Heike, Kopp, Hans-Georg, Essmann, Frank, Aulitzky, Walter E.

“…Abstract For personalized medicine it is crucial that a preclinical model captures the complex tumor biology in vitro in order to individually predict in vivo…”
Get full text

Abstract 4320: Ovarian cancer persister cells are characterized by enhanced ER stress gene expression correlating with poor survival by Böpple, Kathrin, Dong, Meng, Kleih, Markus, Gaißler, Andrea, Oren, Yaara, Henry, Whitney S., Oren, Moshe, Aylon, Yael, Winkler, Bernd, Regev, Aviv, Weinberg, Robert A., Kopp, Hans-Georg, Aulitzky, Walter E., Essmann, Frank

“…Abstract 75% of women suffering from ovarian cancer are diagnosed at late stage of the disease often associated with cancer cell infiltration into the…”
Get full text

Cyclin D1 Driven CDK4 Activity Is Responsible for Hypersensitivity to NOXA Inducing Combination Treatment in Mantle Cell Lymphoma (MCL) Cells by Heine, Simon, Silkenstedt, Elisabeth, Dengler, Michael A, Markus, Kleih, Ott, German, Giménez Carabaza, Neus, Dolors, Colomer, van der Kuip, Heiko, Aulitzky, Walter E.

“…Background: Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma with generally poor outcome. Hallmark of MCL is the t(11;14)(q13;q32)…”
Get full text

Dual Targeting of NOXA/MCL-1 Synergistically Induces Cell Death in Mantle Cell Lymphoma (MCL) Cells by Höring, Elisabeth, Ott, German, Bayha, Christine, Markus, Kleih, Voehringer, Matthias C., van Der Kuip, Heiko, Aulitzky, Walter E.

“…Mantle cell lymphoma (MCL) cells are characterized by a discrepancy between high mRNA and low protein levels of the pro-apoptotic BH3-only protein NOXA…”
Get full text

Abstract 3732: Combined targeting of NOXA and GSTpi effectively kills mantle cell lymphoma cells by Kleih, Markus, Heine, Simon, Dengler, Michael, Schaaf, Lea, Hoering, Elisabeth, Horn, Heike, Ott, German, Aulitzky, Walter E., van der Kuip, Heiko

“…Abstract Mantle cell lymphoma (MCL) is clinically characterized by an aggressive course and only transient response to chemotherapy. Therefore, new treatment…”
Get full text